News and Treatment Updates
Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.
Single cord blood transplantation for acute myeloid leukemia patients aged 60 years or older: a retrospective study in Japan
Originally Published: 02/24/2021
Article Source: External Web Content
This article was originally published here
Ann Hematol. 2021 Feb 23. doi: 10.1007/s00277-021-04464-5. Online ahead of print.
ABSTRACT
The availability of alternative donor sources could allow elderly patients to receive allogeneic hematopoietic cell transplantation (HCT). We retrospectively evaluated the outcomes of single-unit cord blood transplantation (CBT) in 1577 patients aged ≥60 years with acute myeloid leukemia (AML) in Japan between 2002 and 2017. In total, 990 (63%) patients were not in complete remission (CR) at the time of CBT. A myeloablative conditioning regimen (52%) and...
Subcutaneous immunoglobulin in allogeneic hematopoietic cell transplant patients: a prospective study of feasibility, safety, and healthcare resource use
Originally Published: 02/23/2021
Article Source: External Web Content
Abstract
Background
We evaluated feasibility, safety, and total resource use of subcutaneous immunoglobulin (SCIG) in a pilot study of patients who underwent allogeneic hematopoietic cell transplant (HCT) over a 6-month period.
Methods
A total of 20 eligible patients were treated with SCIG at 0.1 g/kg/week for up to 6 months. Patients were matched to 20 concurrent intravenous immunoglobulin (IVIG) controls. Clinical outcomes measured included adverse reactions, healthcare resource use, patient satisfaction, and quality of life (QOL). (ClinicalTrials.gov Identifier: NCT03401268.)
Results...
Scientists discover two unique subtypes of a prominent mutation in patients with AML
Originally Published: 02/16/2021
Article Source: External Web Content
Using advanced RNA sequencing, scientists have identified two unique subtypes of a prominent mutation present in many patients with Acute Myeloid Leukemia (AML) – called NPM1 – that could help predict survival and improve treatment response for patients whose leukemic cells bear the mutation.
In research published Feb. 16, in Nature Communications, a team led by Princess Margaret Cancer Centre Senior Scientists, Drs. Benjamin Haibe-Kains, Aaron Schimmer and Mark Minden, have discovered that within the NPM1 mutation of AML there exists two unique subtypes, one of which can be effectively...
What's New? Foundation Update Newsletter February 2021
Originally Published: 02/16/2021
Article Source: Foundation Update
Trading One Disease for Another: Patients With Chronic Graft-vs-Host Disease May Face Lifelong Complications
Originally Published: 02/10/2021
Article Source: External Web Content
The field of allogeneic stem cell transplantation continues to improve survival for patients with previously incurable blood cancers. However, up to 50% of patients who undergo transplantation with donor cells will develop chronic graft-vs-host disease, a potentially deadly condition that can also cause lifelong complications.
The ASCO Post spoke with Katie Schoeppner, MSW, LICSW, Director of Patient Services at the National Marrow Donor Program (NMDP); Susan K. Stewart, Executive Director, BMT InfoNet; and Meredith Cowden, MA, LPCC-S, of the Meredith A. Cowden Foundation, about the many...
TP53 Modifier Impresses in Early MDS/AML Study
Originally Published: 01/26/2021
Article Source: External Web Content
A drug that targets a common mutation in myelodysplastic syndromes (MDS) led to historically high response rates as initial treatment for MDS and acute myeloid leukemia (AML), a small clinical trial showed.
Overall, 71% of patients with TP53-mutant conditions responded to the combination of eprenetapopt and azacitidine, including complete remissions (CRs) in 44%. A majority of patients with MDS or AML had objective responses. Patients who responded to eprenetapopt lived almost twice as long as those who did not benefit from the treatment.
(Article continues at link above.)
Stem Cell Transplants for Leukemia
Originally Published: 01/21/2021
Article Source: External Web Content
Stem cell transplantation (SCT) offers many people with blood and bone marrow cancers hope for a potential cure. More than 17,500 stem cell transplants are performed in the U.S. annually.
MyLeukemiaTeam sat down with Dr. Matt Kalaycio to better understand stem cell transplantations as a treatment for leukemia. Dr. Kalaycio is the former chair of the department of hematology and medical oncology at the Cleveland Clinic Taussig Center Cancer Institute. An expert in blood cancers, Dr. Kalaycio is currently a professor in the Cleveland Clinic Lerner College of Medicine at Case Western Reserve...
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
Originally Published: 01/19/2021
Article Source: External Web Content
Background
Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19.
Methods
In response to the pandemic, the Center for International Blood and Marrow Transplant Research (CIBMTR) implemented a special form for COVID-19-related data capture on March 27, 2020. All patients—irrespective of age, diagnosis, donor type, graft source...
What's New? Foundation Update Newsletter January 2021
Originally Published: 01/19/2021
Article Source: Foundation Update
Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS
Originally Published: 01/15/2021
Article Source: External Web Content
Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) who had undergone allogeneic hematopoietic cell transplantation (HCT), according to findings from a phase III randomized controlled trial published in Blood Advances.
Despite the disappointing results, “this randomized trial with azacitidine maintenance showed that a prospective trial in the posttransplant setting was feasible and safe but challenging,” the authors, led by...